1. P-132Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. (20th June 2018) Authors: Domenyuk, V; Liu, X; Magee, D; Gatalica, Z; Stark, A; Kennedy, P; Rosenow, M; Barker, A; Berry, D; Poste, G; Halbert, D; Hart, C; Famulok, M; Mayer, G; Korn, M; Miglarese, M; Spetzler, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-132Poly-Ligand Profiling differentiates pancreatic cancer patients according to treatment benefit from gemcitabine+placebo versus gemcitabine+evofosfamide and identifies candidate targets. (20th June 2018) Authors: Domenyuk, V; Liu, X; Magee, D; Gatalica, Z; Stark, A; Kennedy, P; Rosenow, M; Barker, A; Berry, D; Poste, G; Halbert, D; Hart, C; Famulok, M; Mayer, G; Korn, M; Miglarese, M; Spetzler, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗